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OBJECTIVE—Fibrosis is a newly appreciated hallmark of the
pathological alteration of human white adipose tissue (WAT). We
investigated the composition of subcutaneous (scWAT) and
omental WAT (oWAT) ﬁbrosis in obesity and its relationship with
metabolic alterations and surgery-induced weight loss.
RESEARCH DESIGN AND METHODS—Surgical biopsies for
scWAT and oWAT were obtained in 65 obese (BMI 48.2  0.8
kg/m
2) and 9 lean subjects (BMI 22.8  0.7 kg/m
2). Obese
subjects who were candidates for bariatric surgery were
clinically characterized before, 3, 6, and 12 months after
surgery, including fat mass evaluation by dual energy X-ray
absorptiometry. WAT ﬁbrosis was quantiﬁed and character-
ized using quantitative PCR, microscopic observation, and
immunohistochemistry.
RESULTS—Fibrosis amount, distribution and collagen types (I,
III, and VI) present distinct characteristics in lean and obese
subjects and with WAT depots localization (subcutaneous or
omental). Obese subjects had more total ﬁbrosis in oWAT and
had more pericellular ﬁbrosis around adipocytes than lean
subjects in both depots. Macrophages and mastocytes were
highly represented in ﬁbrotic bundles in oWAT, whereas scWAT
was more frequently characterized by hypocellular ﬁbrosis. The
oWAT ﬁbrosis negatively correlated with omental adipocyte
diameters (R  0.30, P  0.02), and with triglyceride levels
(R  0.42, P  0.01), and positively with apoA1 (R  0.25, P 
0.05). Importantly, scWAT ﬁbrosis correlated negatively with fat
mass loss measured at the three time points after surgery.
CONCLUSIONS—Our data suggest differential clinical conse-
quences of ﬁbrosis in human WAT. In oWAT, ﬁbrosis could
contribute to limit adipocyte hypertrophy and is associated with
a better lipid proﬁle, whereas scWAT ﬁbrosis may hamper fat
mass loss induced by surgery. Diabetes 59:2817–2825, 2010
W
hite adipose tissue (WAT) is the main energy
repository in the body. It stores and mobi-
lizes, according to body demand, fatty acids
that have been implicated in the development
of insulin resistance. In turns, the phenotype and the
biology of WAT cellular components are altered by two
major processes: adipose cell hypertrophy and immune
cells accumulation. Inﬂammation, reticulum endoplasmic
stress, and hypoxia are part of the biologic alterations that
attract and retain inﬂammatory cells in WAT (1). Both
adipocytes and nonadipose cells of the stromal vascular
fraction of WAT have been implicated in the secretion of
inﬂammatory molecules and in the development of insulin
resistance (2,3). WAT extracellular matrix (ECM) remod-
eling, which plays a pivotal role in adipogenesis (4) and
tissue architecture (5), is crucial to accommodate obesity-
induced cellular alterations (6). However, the persistence
of an inﬂammation stimulus in WAT may be responsible
for an excessive synthesis of ECM components and sub-
sequent interstitial deposition of ﬁbrotic material. Fibro-
sis, attributed to excessive deposition of ECM proteins, is
a ubiquitous tissue response to an unresolved chronic
inﬂammation (7). We recently highlighted this phenome-
non in obese WAT (8), showing increased expression of
genes encoding extracellular matrix components and dem-
onstrating the presence of ﬁbrosis (8,9). In a small number
of subjects, we scored histologic WAT ﬁbrous tissue using
a picrosirius red staining and observed an increased
abundance of ECM in obese versus lean WAT (8). More-
over, we demonstrated that human adipocyte precursors
secrete ECM components when challenged by macro-
phage secretions (10), emphasizing the prominence of
macrophage-preadipocyte interactions in WAT ﬁbrosis de-
velopment or maintenance. Other inﬂammatory cells ac-
cumulate in obese WAT, including T-lymphocytes and
mast cells (11), and might also participate in the orches-
tration of ﬁbrosis deposition.
The nature and consequences of ECM modiﬁcation in
WAT have been investigated in mice. In db/db obese mice,
various types of collagens are overexpressed in epididy-
mal WAT (12). The predominantly expressed collagen
mRNAs in epididymal WAT encode types I, IV, and VI. In
mice deleted for the col6a1 gene, the lack of collagen VI
associates with increased adipocyte size, both in response
to a high-fat diet and on the obese ob/ob genetic back-
ground (11). A similar phenotype of adipose cell hypertro-
phy has been reported in mice deleted for secreted acidic
cysteine-rich glycoprotein (SPARC), a matricellular glyco-
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(13). A mirror phenotype results from gene invalidation of
the collagenase MT1-matrix metalloproteinase (MT1-
MMP), which leads to the formation of a rigid network of
collagen ﬁbrils and reduced lipid accumulation in the
adipocytes (14). These observations suggest that in-
creased ECM deposition in WAT may contribute to re-
strain adipocyte expansion in obesity.
In humans, the nature of WAT ﬁbrosis and its clinical
relevance are poorly documented and have been ad-
dressed mostly by gene expression evaluation. Subcutane-
ous white adipose tissue (scWAT) collagen VI expression
is increased in Asian Indian subjects compared with
Caucasians, in relation to their higher level of susceptibil-
ity to insulin resistance (12). Pasarica et al. (15) showed
that the expression of collagen VI in human WAT is
upregulated after 8 weeks of overfeeding, concomitant
with increased inﬂammatory gene expression. These two
studies suggest that increased collagen VI deposition
could be a hallmark of WAT deregulation in obesity.
Here, we aimed to characterize more precisely ﬁbrotic
depots in lean and obese subjects and the pathologic
relevance of ﬁbrosis in scWAT and omental white adipose
tissue (oWAT). First, we analyzed qualitatively and quan-
titatively ﬁbrosis in scWAT and oWAT of obese and lean
subjects. Second, we characterized cells structurally
linked with ﬁbrotic depots. Third, we determined if there
is a link between the altered metabolic parameters of
obese and ﬁbrosis quantiﬁed in WAT depots. And fourth,
we examined the consequence of ﬁbrosis accumulation in
the outcome of body fat loss in the model of gastric bypass.
RESEARCH DESIGN AND METHODS
A total of 65 obese subjects (BMI: 48.2  0.8 kg/m
2, age 39.9  1.4 years) were
recruited in the Nutrition Department at the Pitie ´-Salpe ˆtrie `re Hospital (Paris,
France). Patients met the criteria for obesity surgery, i.e., BMI 40 or 35
kg/m
2 with at least one comorbidity (hypertension, type 2 diabetes, dyslipi-
demia, or obstructive sleep apnea syndrome). The subjects had stable weight
(i.e., variations of less than  2 kg) for at least 3 months before the surgery.
Subjects had no acute or chronic inﬂammatory or infectious disease, viral
infection, cancer, or known alcohol consumption (20g per day). Clinical and
biologic parameters were assessed before the gastric bypass surgery and at 3,
6, and 12 months after surgery (data can be found in supplemental Table 1 in
the online appendix available at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0585/DC1). According to the criteria of fasting glycemia over
7 mmol/l or the use of an antidiabetic drug, 21 subjects had type 2 diabetes.
Three of these individuals required insulin therapy, 13 subjects were treated
with metformin and hypolipidemic drugs (either ﬁbrates or statins), and 5
were not treated. Seven female and 2 male volunteers (BMI: 22.8  0.7 kg/m
2,
age 46.0  4.2 years) were recruited as a control group in the same clinical
protocol. These subjects had abdominal programmed surgery (inguinal hernia,
cholecystectomy, hysterectomy, gastro-esophageal reﬂux). They had no in-
ﬂammatory state and accepted the realization of omental and subcutaneous
biopsies in the same location as that of obese subjects. The Ethics Committee
of the Ho ˆtel-Dieu Hospital approved the clinical investigations. Subjects gave
a written informed consent after individual explanation.
Clinical and biological parameters. In obese subjects, body composition
was estimated by whole-body fan-beam dual energy X-ray absorptiometry
scanning (Hologic Discovery W, software v12.6, 2; Hologic, Bedford, MA) (16).
To determine body fat and lean mass repartition, we used speciﬁc measures
and analyses as described (17). Blood samples were collected after an
overnight fast of 12 h. Glycemia was measured enzymatically. Serum insulin
concentrations were measured using a commercial IRMA kit (Bi-insuline
IRMA CisBio International, France). Serum leptin and adiponectin were
determined using a radioimmunoassay kit (Linco Research, St. Louis, MO),
according to the manufacturer’s recommendations, sensitivity: 0.5 ng/ml and
0.8 ng/ml for leptin and adiponectin respectively. Serum level of interleukin-6
(IL-6) was measured by an ultrasensitive ELISA system (Quantikine US, R&D
Systems Europe, U.K., sensitivity 0.04 pg/ml). We measured high-sensitivity
C-reactive protein (hsCRP) using an IMMAGE automatic immunoassay system
(Beckman-Coulter, Fullerton, CA). The sensitivity was 0.02 mg/dl.
Immunohistochemical analysis of adipose tissue. Omental (oWAT) and
subcutaneous (scWAT) biopsies were obtained during gastric or abdominal
surgery in each individual. A portion of each WAT biopsy was immediately
transferred into liquid nitrogen before RNA analysis. The other part was ﬁxed
overnight at 4°C in 4% paraformaldehyde, and processed for standard parafﬁn
embedding. Sections of 5 m were stained as described below and observed
under a Zeiss 20 Axiostar Plus microscope (Zeiss, Germany). Digital images
were captured by a camera (triCCD, Sony, France). Adipocyte diameters and
macrophage number were measured as described (18). We used cell-speciﬁc
stains targeted to macrophages (HAM56, Dakocytomation, Trappes, France)
and to M1 or M2 macrophage subtypes, respectively, CD40 (R&D Systems,
Minneapolis, MN) and CD206 (R&D-Systems, Minneapolis, MN), CD3 (Neo-
marker Microm, Francheville, France) for T-lymphocytes, tryptase (Dakocy-
tomation, Trappes, France) for mast cells. An antibody binding to the 3 chain
of the human collagen VI was used (Abcam, Paris, France). Method speciﬁcity
tests were performed by omission of primary antibodies and use of preim-
mune serum.
Quantiﬁcation and characterization of ﬁbrotic depots. Slides of WAT
biopsies were stained with picrosirius red. Fibrosis analysis was performed by
histomorphometry using an Alphelys platform (Histolab Software, Plaisir,
France) with content color thresholds. The quantiﬁcation of total ﬁbrosis was
expressed as the ratio of ﬁbrous tissue area stained with picrosirius red/total
tissue surface, as described by Henegar et al. (8). The same procedure was
used for quantiﬁcation of pericellular ﬁbrosis, expressed as the ratio of the
sum of stained areas/the sum of ﬁeld surfaces measured in 10 random ﬁelds at
10 magniﬁcation for each biopsy.
Polarized light microscopic observation of WAT ﬁbrosis. We observed
the scWAT and oWAT of lean and obese subjects using polarized light
microscopy on sirius red staining sections allowing visualization of collagen
ﬁbbers with different colors (19). Type I collagen ﬁbbers are orange to red,
whereas the thinner type III collagen ﬁbbers appear yellow to green.
Adipocyte versus stroma vascular fraction gene expression by real-
time quantitative PCR. In 12 patients, surgical subcutaneous AT samples
from lean and obese subjects were separated into adipocytes and stroma
vascular fraction (SVF), as by Clement et al. (20). We evaluated the collagen
type 11, 31, and 61 gene expression changes by reverse transcription and
real-time PCR that were performed as by Clement et al. (21). We used 18S
rRNA (rRNA Control TaqMan Assay kit, Applied Biosystems, Foster City, CA)
as a normalization control. Primer designs can be provided on request.
Isolation of cells from WAT ﬁbrosis and immunoﬂuorescence analysis.
The scWAT and oWAT were digested by 1-h collagenase treatment. The
digested material was ﬁltered and the nondigested ﬁbrosis was collect from
the gauze tissue. After a wash in PBS, ﬁbrosis pieces were put in erythrocyte
lysis buffer for 10 min and digested again in trypsin EDTA buffer for 10 min.
The digested material was ﬁltered, centrifuged, and cultured on glass cover-
slips in appropriate media (DMEM 10% FBS for preadipocytes). A fraction of
the cells were differentiated in adipocytes as described by Lacasa et al. (22).
Immunoﬂuoresence staining was performed as previously described (10).
Clustering analysis. To assess the relationship between ﬁbrosis and bio-
clinical parameters, we used a recent implementation of the k-means algo-
rithm dedicated to longitudinal data (23). We chose the number of clusters to
be three as other values lead to clusters with less than three trajectories.
Statistical analysis. Values are expressed as mean  SD. The Gaussian
distribution of all parameters was tested. Differences between variables were
determined with a nonparametric Wilcoxon test (obese vs. lean subjects);
Correlations were examined with parametric Pearson or nonparametric
Spearman correlation tests, as indicated. For noncontinuous measures, 	
2
tests were used. Results were considered signiﬁcant when P  0.05. For
adjustment (BMI, age, sex, and diabetic state), we applied a multiple linear
regression modeling using least squares means. In that case, continuous
variables were log transformed. Mannova ´ was used for time series analysis.
Statistical analysis was performed with JMP statistics software (SAS Institute,
version 8.0, Cary, NC).
RESULTS
Collagen diversity in ﬁbrous depots. We analyzed
ﬁbrosis in WAT depots by picrosirius red staining in paired
scWAT and oWAT from lean and obese subjects. We
observed a difference in collagen distribution patterns
according to WAT depots. In scWAT, bundles of collagens
ﬁbers were abundant and organized mainly in thick bands
(Fig. 1A, left panel), whereas in oWAT, ﬁbrous bands
appeared more contained, thinner, and they surrounded
lobule-like structures (Fig. 1A, right panel).
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vealed that collagen ﬁbers are organized in bundles of
various thicknesses (Fig. 1B and C, left panels), containing
a few adipocytes isolated from the rest of the parenchyma
(Fig. 1C). Fibrosis was abundant around vessels (Fig. 1D,
left panel). Moreover, thinner collagen ﬁbrils surrounded
adipocytes localized in areas close to ﬁbrotic bundles,
demonstrating pericellular ﬁbrosis (Fig. 1E, left panel).
Interestingly, these adipocytes were a smaller size (44.4 
1.4 m), compared with ﬁbrosis-free cells located in
parenchyma (64.2  2.0 m, n  10, P  0.002). In lean
oWAT sections, this speciﬁc collagen deposition around
adipocytes was rarely present and found only close to
ﬁbrous bundles (data not shown).
When examined with polarized light microscopy, the
same slides demonstrated that type I (labeled in red) and
type III (labeled in green) collagen ﬁbers were present in
bundles of ﬁbrosis (Fig. 1B–D, right panels) and around
adipocytes (Fig. 1E, right panel). Since this technique does
not allow visualization of collagen VI, we performed an
immunohistochemical staining with an anticollagen VI
antibody. Collagen VI deposition was observed around
adipocytes (Fig. 1F) and in higher amounts in obese (right
panel) than in lean oWAT (left panel). In contrast to other
collagen isotypes, collagen VI staining was not found
within the ﬁbrous bundles.
To substantiate the optic microscopy observations, we
explored obese WAT sample with a transmission electron
microscopy. Collagen depots were detected between adi-
pocytes (see supplemental Fig. 1). Some collagen ﬁbrils
display the characteristic periodic striation suggestive of
type I collagen, whereas other collagen ﬁbrils were not
organized into ﬁber structures, a characteristic of type VI
collagen.
Abundance of cell types in adipose tissue ﬁbrotic
depots. Paired scWAT and oWAT biopsies were stained
by hematoxylin/eosine to detect the presence of cells in
ﬁbrosis. Although few nuclei were observed in ﬁbrosis
bundles in scWAT (Fig. 2A, left panel), they were abun-
dantly detected in oWAT ﬁbrosis (Fig. 2A, right panel).
Thus, ﬁbrosis displays distinct characteristics depending
on WAT localization, with more hypocellular ﬁbrosis in
scWAT than in oWAT. PCR analysis on paired samples of
adipocytes and SVF fractions revealed that expression of
three collagens was 4- to 12-fold higher in SVF cells than in
adipocytes (Fig. 2B), indicating that the main cellular
source of collagens in human WAT is within cells of the
stromal vascular fraction.
We designed an assay to identify the cells contained in
WAT ﬁbrosis (Fig. 2C). Since we previously demonstrated
that preadipocyte, a ﬁbroblastic-like cell, secretes ECM
molecules (10), we characterized the phenotype of the
cells released from ﬁbrosis using preadipocytes markers
(Fig. 2D). Indeed, cells associated with ﬁbrosis were able
to differentiate into adipocytes (data not shown) and
stained positive for Pref-1, FABP4, and vimentin, three
proteins expressed in human preadipocytes (24). More-
over, these cells were also SMA positive, consistent with
a ﬁbroblast-like phenotype and express collagen 1.
Inﬂammatory cells were identiﬁed by immunostaining in
ﬁbrous bands in obese oWAT (Fig. 3). Although the
presence of CD3
 T-lymphocytes was minimal, we ob-
served abundant amounts of macrophages stained with M1
(CD40) or M2 (CD206) surface markers in the same
ﬁbrotic area. Using HAM56 antibody on the same serial
slides, we obtained a similar pattern of labeling, indicating
that most CD40
 or CD206
 cells were HAM56
 macro-
phages (data not shown). Additionally, the presence of
mast cells and SMA positive cells were observed in
ﬁbrosis bundles at the proximity of the vessels (Fig. 3). A
similar pattern of immune cells was identiﬁed in scWAT
ﬁbrosis (data not shown), although ﬁbrotic bands ap-
peared less enriched in cells in this depot.
Obesity is associated with increased ﬁbrosis in
adipose tissue. To evaluate the amount of ﬁbrosis in
human WAT, we developed a microscopic image analysis
method to quantify pericellular ﬁbrosis surrounding adi-
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FIG. 1. Picrosirius and collagen VI staining on adipose tissue sections.
A: Comparison of obese scWAT (left panel) and oWAT (right panel)
sections at low magniﬁcation. B–E: Omental WAT section with picro-
sirius staining (left panels). Same section observed with polarized
light (right panels); arrows show accumulation of ﬁbrosis around
adipocytes (i.e., pericellular ﬁbrosis). F: Staining with collagen VI
antibody of lean (left) and obese oWAT (right). V, vessel; B, bundle. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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Collagenase digestion 
Filtration on gauze tissue 
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24h  Cell culture 37°C
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FIG. 2. Cells associated with WAT ﬁbrosis. A: Hematoxylin eosine staining on subcutaneous (left panel) and omental (right panel) WAT
sections. B: Adipocytes and stroma vascular fraction were isolated from 12 subjects. COL1A1, COL3A1, and COL6A1 expression were
quantiﬁed by real-time PCR. *P < 0.005 (C) scWAT and oWAT biopsies were digested with collagenase. The nondigested ﬁbrosis was
collected. Cells that released from the ﬁbrosis were collected and (D) analyzed by immunoﬂuorescence using Pref-1 (red, Cy3-conjugated
anti-rabbit IgG), SMA (green, Cy2-conjugated anti-mouse IgG), FABP4 (red, Cy3-conjugated anti-rabbit IgG), vimentin (green,
Cy2-conjugated anti-mouse IgG), and collagen I (red, Cy3-conjugated anti-rabbit IgG). (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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ﬁbrosis bundles. The amount of total ﬁbrosis was more
than fourfold increased in oWAT of obese versus lean
subjects (Fig. 4A). No difference was found in scWAT.
When pericellular ﬁbrosis was speciﬁcally measured, a
marked increase was found in obese WAT compared with
X40
CD3
X40
tryptase
V
V
X20
CD206
v v
v
X20
CD40
v
v
v
v
v
V
X40
αSMA
FIG. 3. Identiﬁcation of different cell types present in obese oWAT ﬁbrosis. Serial sections of human oWAT were stained for markers of
T-lymphocytes (CD3), mast cells (tryptase), ﬁbroblastic cells (SMA), and for CD40 and CD206 macrophages. The arrows show positive cells
in ﬁbrosis area revealed with DAB system (brown staining). Nucleuses were stained with hematoxylin (blue staining). V, vessel. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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FIG. 4. Total and pericellular ﬁbrosis in WAT of lean and obese subjects. Comparison of total (A) and pericellular (B) ﬁbrosis in scWAT (open
bars) and oWAT (black bars) of 7 lean and 65 obese (OB) subjects. Data show the amount of ﬁbrotic area as a percentage of the total area as
described in RESEARCH DESIGN AND METHODS;* P < 0.05.
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and 3 in oWAT in obese vs. lean, Fig. 4B). The amounts
of both total and pericellular ﬁbrosis in scWAT were
positively correlated with the amounts of ﬁbrosis in oWAT
measured in the same obese subject (R  0.49 for total
ﬁbrosis and R  0.34 for pericellular ﬁbrosis, P  0.05 for
both). These data indicate that ﬁbrosis deposition is likely
to occur concomitantly in the two adipose tissue sites
investigated.
Omental ﬁbrosis associates with adipocyte size and
lipid parameters. To examine the pathophysiologic rele-
vance of ﬁbrosis in obese WAT, we investigated the
relationships between total ﬁbrosis and clinical and bio-
logic parameters in 65 obese subjects (Table 1). No
correlation was found between total ﬁbrosis in oWAT or
scWAT and age, BMI, or fat mass in this population.
Interestingly, we found that obese men had less ﬁbrosis in
oWAT than women. No difference was observed in the
amount of ﬁbrosis according to blood-derived glycemic
parameters or diabetic status. Circulating IL-6 or hsCRP,
two representative markers of systemic inﬂammation in
obesity, did not correlate with ﬁbrosis, whatever the
depot. Finally, oWAT, but not scWAT ﬁbrosis, was related
to blood lipid parameters, demonstrating a negative cor-
relation with triglycerides and a positive correlation with
HDL cholesterol, and Apo lipoprotein A1. Omental ﬁbrosis
also negatively correlated with adipocyte size in the same
depot.
We performed a multivariate analysis, taking into ac-
count sex, diabetic status, and log transformed values of
age, BMI, and total omental ﬁbrosis. This analysis con-
ﬁrmed the strong negative association between circulating
triglycerides and omental ﬁbrosis. This association re-
mained signiﬁcant after adding adipocyte diameter in the
model, suggesting that these two factors are related to
triglyceride levels (supplemental Table 2).
Diminished fat mass loss in gastric bypass associates
with subcutaneous adipose tissue ﬁbrosis. The 65
patients were candidate for gastric bypass intervention
and were followed for a year with clinical check points at
3, 6, and 12 months after surgery (Table 2). Although
gastric bypass is a drastic procedure associated with
major body fat loss and reduced adipocyte size, there is a
well known individual variation in the amount of weight
and fat loss after a year (17). Initial BMI, age, and
metabolic state (i.e., diabetes) were shown to be factors
modulating the amount of weight loss (25,26). We made
the hypothesis that the amount of ﬁbrosis in fat depots
associate with fat mass loss. Figure 5A shows the decrease
of fat mass expressed as a percentage of the initial value.
TABLE 1
Correlation analysis between total ﬁbrosis amount in scWAT and
oWAT and clinical characteristics in 65 obese patients
Fibrosis in
scWAT Fibrosis in oWAT
R P R P
Age 0.06 ns 0.01 ns
Sex* ns 0.01
Adiposity markers
BMI 0.06 ns 0.12 ns
Fat mass 0.11 ns 0.18 ns
Adipocytes diameter 0.01 ns 0.30 0.02
Plasma parameters
Triglycerides 0.22 ns 0.42 0.01
HDL cholesterol 0.03 ns 0.28 0.03
Apolipoprotein A1 0.05 ns 0.25 0.05
Diabetic status* ns ns
Quicki 0.04 ns 0.03 ns
Inﬂammatory markers
IL-6 0.20 ns 0.16 ns
hsCRP 0.11 ns 0.07 ns
*Statistical analysis with 	
2 test for noncontinuous measures. ns, not
signiﬁcant; Quicki, quantitative insulin sensitivity check index.
TABLE 2
Clinical and biologic characteristics of obese subjects before surgery, 3 months, 6 months, and 1 year after surgery
Before
bypass
3 Months
after bypass
6 Months
after bypass
1 Year after
bypass
Mannova ´
(P value)
Adiposity markers
Body weight(kg) 135.03  3.08 111.75  2.84 102.04  2.67 93.39  2.72  0.0001
BMI (kg/m
2) 48.21  0.82 39.78  0.78 36.28  0.78 33.30  0.83  0.0001
Fat mass (% weight) 46.21  0.69 43.15  0.71 39.24  0.84 34.53  0.89  0.0001
Leptin (ng/ml) 63.05  3.16 32.85  2.15 23.9  1.74 18.53  0.89  0.0001
Plasma glucose homeostasis
Glycaemia (mmol/l) 6.55  0.37 5.18  0.13 4.87  0.14 4.74  0.11  0.0001
Insulinemia (mU/ml) 19.02  1.81 8.7  0.47 6.9  4.36 7.23  0.99  0.0001
Adiponectin (g/ml) 6.08  0.36 7.77  0.43 9.95  0.83 10.26  0.67  0.0001
Diabetic (%)* 32.3 14.3 9.5 8.6  0.005
Plasma lipid homeostasis
Total cholesterol (mmol/l) 5.00  0.12 4.47  0.11 4.36  0.11 4.28  0.10  0.0001
Total triglycerides (mmol/l) 1.53  0.10 1.22  0.06 1.08  0.06 0.89  0.04  0.0001
HDL cholesterol (mmol/l) 1.28  0.05 1.23  0.04 1.35  0.05 1.50  0.04  0.0001
Liver test
AST 24.51  1.49 28.13  1.59 26.33  5.85 21.18  1.03 0.0035
ALT 35.46  3.49 38.31  3.32 25.33  2.59 24.27  4.29 0.0287
GGT 48.90  5.26 29.75  2.90 40.38  17.55 22.66  2.13  0.0001
Inﬂammatory markers
Plasma hsCRP (mg/l) 0.91  0.08 0.61  0.09 0.39  0.05 0.33  0.11  0.0001
Plasma IL-6 (pg/ml) 3.94  0.32 3.46  0.29 3.22  0.39 2.27  0.38 0.62
*Statistical analysis with McNemar 	
2 test for noncontinuous measures. AST, aspartate aminotransferase; ALT, alanine aminotransferase;
GGT, -glutamyl transferase.
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negative correlations between the amount of total ﬁbrosis
in scWAT before intervention and the percentage of fat
mass loss at 3 months (R  0.39, P  0.004), 6 months
(R  0.31, P  0.030), and 12 months (R  0.30, P 
0.040) after surgery. Similar negative correlations were
found between pericellular ﬁbrosis and fat mass loss at 3
months (R  0.23, P  0.008), 6 months (R  0.32, P 
0.020), and 12 months (R  0.30, P  0.030).
Since individual responses were highly variable, we
used a clustering approach enabling grouping of the
subjects in three partitions. Supplemental Table 3 summa-
rizes the clinical differences between the three clustered
groups. Subjects in group C lost less body fat mass after
surgery compared with A and B groups. Group C subjects
had higher BMI, no difference in serum adiponectin,
triglycerides, and cholesterol, and markedly increased
plasmatic IL-6. This prompted us to perform a multivariate
models analysis to explain the percentage of fat mass loss
at 3, 6, and 12 months after surgery, using IL-6 and scWAT
ﬁbrosis as explicative variables. Adjustment with IL-6 only
marginally modiﬁed the signiﬁcant associations between
scWAT ﬁbrosis and the percentage of fat mass loss at the
follow-up time points (supplemental Table 4).
We then compared ﬁbrotic depots and clinical data
before the intervention in the three clustered groups A, B,
and C. Subjects in group C demonstrated a trend in
increased total ﬁbrosis and signiﬁcantly higher pericellular
ﬁbrosis amount in scWAT (P  0.008), compared with A or
B subject groups (Fig. 5B).
DISCUSSION
We performed here a detailed analysis of the nature of
ﬁbrosis in two distinct WAT depots and explored its
association with clinical parameters of obese patients. We
show, for the ﬁrst time, the presence of different patterns
of ﬁbrous depots and detailed collagen ﬁbers organization
in human WAT. Fibrosis appears distributed in bundles of
variable thickness, which may contain some adipocytes
isolated from the rest of the parenchyma. The detailed
observation of ﬁbrous structure also shows ﬁbrosis span-
ning around each adipocyte (i.e., pericellular ﬁbrosis), a
ﬁber disposition that may directly affect adipose cell
biology. Interestingly, we observed that some adipocytes
engulfed in ﬁbrosis stained negative for perilipin (supple-
mental Fig. 2), reminiscent of perilipin-negative adipocytes
previously described in crown-like structures of macro-
phages (27). This suggests that ﬁbrosis could be a re-
sponse to signals emerging from dysfunctional or dying
adipocytes.
Type I and III collagens were more frequently observed
in ﬁbrous bundles, whereas type VI collagen surrounded
parenchymal adipocytes, particularly in obese subjects.
Thus, collagen VI may represent a small proportion of total
collagens in human WAT, at variance with mouse WAT in
which collagen VI is abundantly expressed (11). In a large
population of normal weight and overweight males,
Pasarica et al. (15) showed that type VI collagen gene
expression in scWAT increases with BMI. In our popula-
tion of subjects with extreme BMI, although we cannot
exclude increased collagen VI expression in WAT, no
relationship was established between BMI and total colla-
gen quantiﬁcation based on picrosirius staining.
One important ﬁnding of this study is the negative
relationship between the amount of oWAT ﬁbrosis and
adipocyte size, on the one hand, and circulating triglycer-
ides, on the other hand. Multivariate analysis showed that
these factors are closely related, suggesting that omental
ﬁbrosis inﬂuences the circulating triglycerides level by
limiting adipocyte size. The fact that obese patients with
smaller adipocyte cell size have a better lipid proﬁle is in
agreement with recent observations by Arner E. et al. (2)
showing that women with adipocyte hypertrophy have a
more adverse metabolic proﬁle than women with cellular
hyperplasia at a similar BMI level. Our observation sug-
gests that the generation of omental ﬁbrosis could contrib-
ute to limit adipocyte expansion, thus acting as an
adaptation mechanism that contributes to slowing down
the negative effect of adipocyte hypertrophy. Of note,
these relationships were not found in scWAT, suggesting
differential consequences of the presence of ﬁbrosis de-
pending on fat depot localization. Additionally, our data
suggest that the presence of high levels of ﬁbrosis in WAT
does not markedly inﬂuence glucose homeostasis, since
no signiﬁcant correlation was found between the amount
of ﬁbrosis and glycemic parameters in our population of
morbidly obese subjects.
The mechanisms and kinetic of ﬁbrotic depot accumu-
lations are unknown and difﬁcult to study in humans. In
particular, the suggested link between ﬁbrotic depots and
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FIG. 5. Clustering of fat mass loss proﬁles in obese subjects and
relation with scWAT ﬁbrosis. A: Individual fat mass changes at 3, 6, and
12 months after surgery were clustered using a recently implemented
k-means algorithm dedicated to longitudinal data. The panel shows
individual fat mass changes expressed as change at 3, 6, or 12 month/
time 0 values. Three clusters were built. A, B, and C are the mean of
fat-mass changes in each clustered group. B: Mean of scWAT total
ﬁbrosis or pericellular ﬁbrosis in each clustered group, A, B, and C.
Pericellular ﬁbrosis is signiﬁcantly more abundant in cluster C com-
pared with A and B. *P  0.01 **P  0.001.
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(12,28) does not appear straightforward based on our data.
Fibrosis was more abundant in subcutaneous than in
omental depots where inﬂammatory cell accumulation is
greater. We found no correlations between ﬁbrosis quan-
tiﬁcation and systemic low grade inﬂammation based on
IL-6 or C-reactive protein circulating measures. Macro-
phages of both M1 and M2 phenotype and mast cells were
the main immune cells found in ﬁbrotic area, where T
lymphocytes were less frequent. Fibrosis is typically con-
sidered a ﬁbroproliferative disorder, with the uncontrolled
production of ECM components by ﬁbroblasts activated
by an inﬂammatory microenvironment. Although we found
SMA-positive cells in ﬁbrotic bands, immunoﬂuores-
cence also highlighted that these cells display features of
preadipocytes. This is in agreement with our previous
experiments in which we showed a capacity of human
preadipocytes to secrete ﬁbrotic factors under inﬂamma-
tory conditions (8,10).
Recent studies suggest that adiponectin exerts antiﬁ-
brotic effects partly by reducing proﬁbrotic TGF- signal-
ing in experimental models of liver or cardiac ﬁbrosis
(29,30). Although measures were not available for the lean
group in this study, it is well established that adiponectin
levels are reduced in obesity. This feature could contribute
to promotion of ﬁbrosis deposition in WAT. However, our
data failed to demonstrate a relationship between adi-
ponectin and WAT ﬁbrosis in the obese group, and lower
adiponectinemia did not discriminate subjects included in
cluster C characterized by higher amounts of pericellular
ﬁbrosis in scWAT (supplemental Table 3). Further studies
investigating the evolution of WAT ﬁbrosis in relation with
the increase in plasma adiponectin induced by weight loss
would help to substantiate the implication of adiponectin
in human WAT ﬁbrosis.
Interestingly, we found a negative correlation be-
tween the percentage of total ﬁbrosis in scWAT and the
percentage of fat mass loss in patients after gastric
bypass surgery, a situation leading to drastic fat mass
loss and adipocyte shrinkage. Subjects with more WAT
ﬁbrosis lose less fat mass at 3, 6, and 12 months after
surgery. Although this surgical model is extremely efﬁ-
cient for rapid fat mass loss in obese patients, there is
important individual variability in the response to the
intervention (31). This is also illustrated by the cluster-
ing of individual’s fat mass loss after surgery. Classi-
cally, subjects with higher BMI before surgery lose more
weight and fat mass after bariatric surgery (32). Age and
metabolic situation also explain the different weight
loss proﬁles (25). Strikingly, in our study, although
group C had higher BMI, they had the less favorable fat
loss proﬁle. This group also displayed high levels of IL-6.
Of note, the relationship between scWAT ﬁbrosis and
resistance to fat mass loss was only slightly inﬂuenced
after adjustment for IL-6. We suggest that both high
levels of scWAT ﬁbrosis and systemic inﬂammation
inﬂuenced the individual capacity to lose fat mass in
group C subjects. Whether subcutaneous ﬁbrosis could
be used as a good predictor of weight loss in surgical or
dietary intervention studies, we obviously need more
investigations in larger groups of individuals and in
those with other nutritional challenges. More studies
are also needed to follow the evolution of ﬁbrotic
depots after weight loss.
This study provides new insight about the composition
in WAT ﬁbrosis showing a different pattern and distinct
physiopathologic signiﬁcance in subcutaneous and omen-
tal WAT. Indeed, these two types of ﬁbrosis show differ-
ences in their organization, quantity, nature and their
inﬂuence in the clinical parameters of obese patients. A
major ﬁnding is the diminished fat mass loss in patients
with high level of ﬁbrosis in their subcutaneous adipose
tissue, which designs this alteration as a potential predic-
tive factor for resistance to weight loss in obese subjects.
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